Arbutus to Present at Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:35 pm EST. The company focuses on developing cures for chronic hepatitis B virus (HBV) infection and treatments for coronaviruses, including COVID-19. Attendees can access the live webcast through the company's website, with an archived replay available afterward. Arbutus continues to advance multiple drug candidates aimed at potentially curing chronic HBV.

WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:35 pm EST (5:35 pm GMT).

A live webcast of the presentation can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com

FAQ

When is William Collier presenting for Arbutus Biopharma at the Jefferies Conference?

William Collier will present on November 17, 2020, at 12:35 pm EST.

What is the main focus of Arbutus Biopharma?

Arbutus Biopharma primarily focuses on developing cures for chronic hepatitis B virus (HBV) infection and therapies for coronaviruses, including COVID-19.

How can I access the live webcast of the Arbutus Biopharma presentation?

The live webcast can be accessed through the Investors section of Arbutus' website.

Will there be a replay of the Arbutus Biopharma conference presentation?

Yes, an archived replay of the webcast will be available on the company's website after the conference.